Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci200438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Galina Semenova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Immunoconjugates, bcl-X Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Congressionally Directed Medical Research Programs.
Abstract (Originalsprache)
Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive subtype of prostate cancer (PC) without curative treatments. Antibody-drug conjugates (ADCs) emerged as promising cancer therapeutics that selectively deliver cytotoxic agents (payloads) to the tumors. Although ADCs have been successfully applied to treat hematological and solid tumors, ADC monotherapy has not demonstrated durable responses in mCRPC, and mechanisms of PC resistance to ADCs have not been thoroughly investigated. Our study aimed to improve ADC efficacy using an integrated approach for a custom ADC design and multiplexing. To nominate rational combinations of ADC targets and payloads, we (a) examined protein coexpression of 3 clinically relevant surface antigens — B7-H3, PSMA, and STEAP1 — in human mCRPCs and (b) screened established ADC payloads and their combinations in mCRPC cell lines with different molecular backgrounds. Identified synergistic interactions between DNA-damaging payloads and the BCL-XL inhibitor A-1331852 as well as their coordinated induction of the intrinsic apoptosis pathway were evaluated in PC cell lines. Functional relevance between isolated p53 loss and PC responses to 3 genotoxic ADCs — B7-H3–seco-DUBA, PSMA-SG3249, and STEAP1-DXd — and their combinations with A-1331852 were established using genetic knockout models. Lastly, enhanced in vivo antitumor activity of vobramitamab duocarmazine by systemic A-1331852 was shown. Collectively, our findings provide rationale for development of ADC therapies combining genotoxic payloads with BCL-XL inhibitors for mCRPC. The study presents a framework for combinations of antibody-drug conjugate targets and payloads that may be applied to improve the treatment of late-stage prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA.
- Human Biology Division and.
- Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
- Congressionally Directed Medical Research Programs
- Prostate Cancer Foundation
- Institute for Prostate Cancer Research
Zitieren
APA
Semenova, G., Frank, S. B., Dumpit, R., Han, W., Coleman, I., Gulati, R., Dirican, C. D., Arman, T., Maruwan, J., Morrissey, C., Haffner, M. C., Nelson, P. S., & Lee, J. K. (2026). Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci200438
Vancouver
Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, et al. Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. Journal of Clinical Investigation. 2026. doi:10.1172/jci200438
BibTeX
@article{Semenova2026,
author = {Semenova, Galina and Frank, Sander B and Dumpit, Ruth and Han, Wanting and Coleman, Ilsa and Gulati, Roman and Dirican, Canan D and Arman, Tarana and Maruwan, Jessica and Morrissey, Colm and Haffner, Michael C and Nelson, Peter S and Lee, John K},
title = {Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci200438}
}
EUVIMED